0001213900-23-013271.txt : 20230221 0001213900-23-013271.hdr.sgml : 20230221 20230221160121 ACCESSION NUMBER: 0001213900-23-013271 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230221 FILED AS OF DATE: 20230221 DATE AS OF CHANGE: 20230221 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PolyPid Ltd. CENTRAL INDEX KEY: 0001611842 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38428 FILM NUMBER: 23647975 BUSINESS ADDRESS: STREET 1: 18 HASIVIM STREET CITY: PETACH TIKVA STATE: L3 ZIP: 495376 BUSINESS PHONE: 972-74-7195700 MAIL ADDRESS: STREET 1: 18 HASIVIM STREET CITY: PETACH TIKVA STATE: L3 ZIP: 495376 6-K 1 ea174014-6k_polypid.htm REPORT OF FOREIGN PRIVATE ISSUER

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of: February 2023 (Report No. 2)

 

Commission File Number: 001-38428

 

PolyPid Ltd.

(Translation of registrant’s name into English)

 

18 Hasivim Street

Petach Tikva 495376, Israel

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

☒ Form 20-F    ☐ Form 40-F

 

 

 

 

 

 

CONTENTS

 

Dr. Noam Emanuel, Ph.D., co- founder and Chief Scientific Officer of PolyPid Ltd. (the “Registrant”), will retire from the Registrant during the second quarter of 2023. The Registrant and Dr. Emanuel intend to explore a potential future engagement under a consultancy agreement.

 

This Report on Form 6-K is incorporated by reference into the Registrant’s registration statements on Form F-3 (File No. 333-257651) and Form S-8 (File No. 333-239517), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  POLYPID LTD.
     
Date: February 21, 2023 By: /s/ Dikla Czaczkes Akselbrad
    Name:  Dikla Czaczkes Akselbrad
    Title: Chief Executive Officer

 

 

 

2